Concord Biotech’s Unit-II Formulation Facility Receives Successful Inspection from Kenyan and Ugandan Authorities
Concord Biotech Ltd has announced the successful completion of inspections conducted at its Unit-II formulation facility by international regulatory bodies. The inspection covered facilities in relation to their operations, concluding after a period spanning June 18, 2026, to June 24, 2026.The oversight was provided jointly by the Pharmacy and Poisons Board (PPB) from Kenya and the National Drug Authority (NDA) from Uganda. The successful completion of these dual inspections is highlighted as a significant development in Concord Biotech’s journey toward global growth.
According to the company, this achievement underscores its dedication to maintaining the highest standards of quality and regulatory excellence. The inspection results are set to strengthen the company's global manufacturing capabilities and regulatory footprint.
CONCORDBIO Stock Price Movement
Shares of Concord Biotech Limited are edging higher to ₹1299.1 as of 10:07 AM, climbing 0.63% in live trading after gaining ₹8.10. The stock is currently maintaining a solid upward trajectory amidst heavy activity and trades within its daily range, having touched lows near ₹1285 on a volume of 48,030 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.